1 to 9 of 16 results

Johnson & Johnson reveals 12 new life sciences alliances

Johnson & Johnson reveals 12 new life sciences alliances


US health care giant Johnson & Johnson, through its J&J Innovation unit, today announced 12 new alliances…

Aduro BioTechAnti-Arthritics/RheumaticsCardio-vascularFinancialJohnson & JohnsonMetabolicsMinerva NeurosciencesNavitor PharmaceuticalsNeurologicalOncologyPadlock TherapeuticsPharmaceuticalResearchRodin Therapeutics

Actavis challenges Multaq and Colcrys patents


Ireland-headquartered generic drugmaker Actavis revealed on Friday (February 28) that French pharma giant…

ActavisAnti-Arthritics/RheumaticsCardio-vascularColcrysGenericsLegalMultaqNorth AmericaPatents & Trade marksRegulationSanofiTakeda PharmaceuticalsUSA

EMA Pharmacovigilance unit updates on Iclusig, diacerein and acipimox

EMA Pharmacovigilance unit updates on Iclusig, diacerein and acipimox


At its November 4-7 meetings, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee…

acipimoxAnti-Arthritics/RheumaticsAriad PharmaceuticalsCardio-vasculardiacereinEuropeIclusigOncologyPharmaceuticalRegulation

Amgen and Astellas link up on drugs for unmet medical needs in Japan


World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

News briefs: Pfizer's filiburvir; Sanofi's Plavix; EMA sued over transparency


Among a batch of news reported over the weekend, US drugs behemoth Pfizer (NYSE: PFE) has halted development…

AbbVieAnti-Arthritics/RheumaticsAnti-viralsBiotechnologyCardio-vascularEuropefiliburvirHumiraInterMuneNorth AmericaPfizerPharmaceuticalPlavixRegulationResearchSanofi

Merck & Co highlights pipeline progress; plans eight US filings in 2012-


US pharma giant Merck & Co (NYSE:MRK) hosted an upbeat R&D and Business Briefing yesterday, where it…

Anti-Arthritics/RheumaticsBridonCardio-vascularFinancialMerck & CoNeurologicalodanacatibOncologyPharmaceuticalRegulationResearchsuvorexantTredaptive

EMA says risk-benefit of ARBs positive; acts on Advagraf and Protelos/Osseor


In a flurry of late news yesterday from the European Medicines Agency and its Committee for Medicinal…

AdvagrafAnti-Arthritics/RheumaticsAstellas PharmaCardio-vascularEuropeImmunologicalsPharmaceuticalProtelosRegulationServier

1 to 9 of 16 results

Back to top